On January 31, OIG released a proposed rule that, if approved, may have broad implications for pharmaceutical manufacturers and pharmacy benefit managers, and may change the structure for drug pricing. OIG is seeking comments on the proposal by April 7, 2019 in advance of issuing a final rule.